Invivyd Q3 Loss Widens to $33.5M; DECLARATION Data Now 'Imminent' After FDA Talks
IVVD is trading near its 52-week low of $0.528 (6.5% above the low).
Summary
Invivyd posted a $33.5 million Q3 loss on $15.4 million of PEMGARDA revenue and pushed the DECLARATION Phase 3 data to 'imminently' while working with the FDA on its accelerated approval path. Cash stands at $126.4 million.
Key Events · Earnings and Guidance · IVVD
-
Q3 Loss Widens Sharply
Net loss was $33.5 million, or $0.10 per share, versus $10.5 million a year earlier, as R&D rose to $18.7 million from $8.0 million and SG&A to $30.3 million from $15.0 million.
-
PEMGARDA Revenue Grows 18%
Net product revenue reached $15.4 million for the quarter, up from $13.1 million in Q3 2025, despite the announced mid-2027 EUA termination.
-
DECLARATION Readout Pushed to 'Imminent'
Data timing was updated following FDA dialogue to refine the Accelerated Approval approach for VYD2311 and extend the accelerated pathway to future antibodies, including the measles candidate.
-
Cash Falls to $126.4M
Cash and cash equivalents were $126.4 million at September 30, 2026, down from $226.7 million at December 31, 2025, against a $33.5 million quarterly loss.
Analysis · IVVD · Life Sciences
The quarter itself is ugly: the net loss more than tripled to $33.5 million from $10.5 million as R&D and SG&A roughly doubled on the VYD2311 program, and cash fell to $126.4 million from $226.7 million at year-end. Against that backdrop, the real news is the DECLARATION Phase 3 readout slipping to 'imminently' while management renegotiates the Accelerated Approval path with the FDA — a delay, but one framed as broadening the accelerated route to future antibodies including the measles candidate. With PEMGARDA's EUA terminating in mid-2027 and going-concern doubt previously disclosed, VYD2311 is the whole thesis and this readout is the binary event.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IVVD was trading at $0.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $171.6M. The 52-week trading range was $0.53 to $3.07. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.